blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4227321

EP4227321 - ANTIBODIES TARGETING THE B-CELL RECEPTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA AND USES THEREOF [Right-click to bookmark this link]
Former [2023/33]ANTIBODIES TARGETING THE B-CELL RECEPTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR USE IN TREATMENT OF CLL
[2023/35]
StatusExamination is in progress
Status updated on  06.10.2023
Database last updated on 12.12.2024
FormerRequest for examination was made
Status updated on  14.07.2023
Most recent event   Tooltip22.11.2024Staypublished on 25.12.2024 [2024/52]
Applicant(s)For all designated states
SinABioSolution GmbH
Klaus-Groth-Strasse 8
14050 Berlin / DE
[2024/13]
Former [2024/01]For all designated states
AVA Lifescience GmbH
Norsinger Strasse 30
79189 Bad Krozingen / DE
Former [2023/33]For all designated states
AVA Lifescience GmbH
Ferdinand-Porsche Strasse 5/1
79211 Denzlingen / DE
Inventor(s)01 / DÜHREN-VON MINDEN, Marcus
79379 Müllheim / DE
 [2023/33]
Representative(s)ETL IP Patent- und Rechtsanwaltsgesellschaft mbH
Clayallee 343
14169 Berlin / DE
[N/P]
Former [2023/33]Cacace, Sabrina Rosella
Immentalstraße 38
79104 Freiburg / DE
Application number, filing date22156205.110.02.2022
[2023/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4227321
Date:16.08.2023
Language:EN
[2023/33]
Type: A8 Corrected patent application 
No.:EP4227321
Date:27.09.2023
[2023/39]
Search report(s)(Supplementary) European search report - dispatched on:EP19.07.2022
ClassificationIPC:C07K16/30, A61K39/395, A61P35/02
[2023/33]
CPC:
C07K16/3061 (EP); C07K16/2803 (KR,US); A61K39/39566 (EP);
A61P35/00 (US); A61P35/02 (EP,KR); A61K2039/505 (EP,KR);
A61K2039/545 (KR); C07K2317/24 (KR,US); C07K2317/56 (EP);
C07K2317/73 (KR); C07K2317/92 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/13]
Former [2023/33]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:ANTIKÖRPER GEGEN DEN B-ZELL REZEPTOR CHRONISCHER LYMPHATISCHER LEUKÄMIE UND VERWENDUNGEN DAVON[2023/35]
English:ANTIBODIES TARGETING THE B-CELL RECEPTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA AND USES THEREOF[2023/35]
French:ANTICORPS CONTRE LE RECEPTEUR DES CELLULES B DE LA LEUCEMIE LYMPHOIDE CHRONIQUE ET LEUR UTILISATION[2023/35]
Former [2023/33]ANTIKÖRPER GEGEN DEN B-ZELL REZEPTOR CHRONISCHER LYMPHATISCHER LEUKÄMIE (CLL) ZUR VERWENDUNG BEI DER BEHANDLUNG VON CLL
Former [2023/33]ANTIBODIES TARGETING THE B-CELL RECEPTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR USE IN TREATMENT OF CLL
Former [2023/33]ANTICORPS CONTRE LE RECEPTEUR DES CELLULES B DE LA LEUCEMIE LYMPHOIDE CHRONIQUE (LLC) UTILISÉES DANS LE TRAITEMENT DE LLC
Examination procedure16.02.2022Examination requested  [2023/33]
19.07.2022Date on which the examining division has become responsible
05.10.2023Despatch of a communication from the examining division (Time limit: M06)
08.05.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
08.07.2024Reply to a communication from the examining division
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
08.07.2024Request for further processing filed
08.07.2024Full payment received (date of receipt of payment)
Request granted
16.07.2024Decision despatched
Fees paidRenewal fee
28.02.2024Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Stay/Interruption14.11.2024Stay of proceedings[2024/52]
Documents cited:Search[AD]WO2019008129  (AVA LIFESCIENCE GMBH [DE]) [AD] 1-13 * example 1 * * sequences 9, 10 * * claims 15,16 *;
 [A]WO2020127827  (AVA LIFESCIENCE GMBH [DE]) [A] 1-13 * example 1 * * sequences 5, 6 *;
 [A]WO2020221466  (AVA LIFESCIENCE GMBH [DE]) [A] 1-13 * example 1 * * sequences 9, 10 * * claims 7, 8 *;
 [AD]  - MAITY PALASH C. ET AL, "IGLV3-21 * 01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 117, no. 8, doi:10.1073/pnas.1913810117, ISSN 0027-8424, (20200211), pages 4320 - 4327, URL: https://www.pnas.org/doi/full/10.1073/pnas.1913810117, XP055939305 [AD] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.1913810117
    [ ] - MAITY PALASH C. ET AL, "IGLV3-21 * 01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling - supporting information", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 117, no. 8, doi:10.1073/pnas.1913810117, ISSN 0027-8424, (20200211), pages 4320 - 4327, URL: https://www.pnas.org/doi/full/10.1073/pnas.1913810117, XP055939309 [ ] * table on p.4 suppl. info. *

DOI:   http://dx.doi.org/10.1073/pnas.1913810117
 [A]  - PATEL KRISH ET AL, "Current and future treatment strategies in chronic lymphocytic leukemia", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 14, no. 1, doi:10.1186/s13045-021-01054-w, (20210426), URL: https://link.springer.com/article/10.1186/s13045-021-01054-w/fulltext.html, XP055939369 [A] 1-13 * the whole document *

DOI:   http://dx.doi.org/10.1186/s13045-021-01054-w
 [A]  - JAMES TORCHIA ET AL, "Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20160425), vol. 113, no. 19, doi:10.1073/pnas.1603335113, ISSN 0027-8424, pages 5376 - 5381, XP055565565 [A] 1-13

DOI:   http://dx.doi.org/10.1073/pnas.1603335113
 [A]  - MACARRÓN PALACIOS ARTURO ET AL, "Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies", FRONTIERS IN IMMUNOLOGY, Lausanne, CH, (20201126), vol. 11, doi:10.3389/fimmu.2020.560244, ISSN 1664-3224, XP055880182 [A] 1-13

DOI:   http://dx.doi.org/10.3389/fimmu.2020.560244
 [T]  - SAWALHA YAZEED ET AL, "Novel treatments in B cell non-Hodgkin's lymphomas", BMJ, doi:10.1136/bmj-2020-063439, (20220420), page e063439, URL: https://www.bmj.com/content/377/bmj-2020-063439, XP055939610

DOI:   http://dx.doi.org/10.1136/bmj-2020-063439
by applicantWO9951642
 US6194551
 WO2019008129
    - ROZ-MAN CMONTSERRAT E, "Chronic lymphocytic leukemia", N Engl J Med, (19950000), vol. 333, pages 1052 - 1057
    - KIPPS TJSTEVENSON FKWU CJCROCE CMPACKHAM GWIERDA WG et al., "Chronic lymphocytic leukemia", Nat Rev Dis Primers, (20170000), vol. 3, pages 1 - 12
    - BURGER JACHIORAZZI N., "B cell receptor signaling in chronic lymphocytic leukemia", Trends Immunol, (20130000), vol. 34, pages 592 - 601
    - FLASWINKEL, H.RETH, M., "Dual role of the tyrosine activation motif of the Ig-alpha protein during signal transduction via the B cell antigen receptor", EMBO J., (19940000), vol. 13, pages 83 - 89
    - STEVENSON FKKRYSOV SDAVIES AJSTEELE AJ, "Packham G. B-cell receptor signaling in chronic lymphocytic leukemia", Blood, (20110000), vol. 118, pages 4313 - 4320
    - CASOLA SOTIPOBY KIALIMZHANOV M et al., "B cell receptor signal strength determines B cell fate", Nat Immunol, (20040000), vol. 5, doi:10.1038/ni1036, pages 317 - 27, XP055106262

DOI:   http://dx.doi.org/10.1038/ni1036
    - DUHREN-VON MINDEN M et al., "Chronic lymphocytic leukemia is driven by antigen-independent cell-autonomous signalling", Nature, (20120000), vol. 489, pages 309 - 313
    - GOBESSI SLAURENTI LLONGO PGCARSETTI LBERNO VSICA S et al., "Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells", Leukemia, (20090000), vol. 23, pages 686 - 697
    - RINGSHAUSEN ISCHNELLER FBOGNER CHIPP SDUYSTER JPESCHEL C et al., "Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase C delta", Blood, (20020000), vol. 100, pages 3741 - 3748
    - PLATE JM, "P13-kinase regulates survival of chronic lymphocytic leukemia B- cells by preventing caspase 8 activation", Leuk Lymphoma, (20040000), vol. 45, pages 1519 - 1529
    - SAINZ-PEREZ AGARY-GOUY HPORTIER ADAVI FMERLE-BERAL HGALANAUD P et al., "High Mda-7 expression promotes malignant cell survival and p38 MAP kinase activation in chronic lymphocytic leukemia", Leukemia, (20060000), vol. 20, doi:10.1038/sj.leu.2404073, pages 498 - 504, XP002469144

DOI:   http://dx.doi.org/10.1038/sj.leu.2404073
    - LOEDER S et al., "A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia", Cancer Res., (20090000), vol. 69, pages 8977 - 8986
    - PETLICKOVSKI ALAURENTI LLI XMARIETTI SCHIUSOLO PSICA SLEONE GEFREMOV DG., "Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells", Blood, (20050000), vol. 105, pages 4820 - 4827
    - STAMATOPOULOS KBELESSI CMORENO C et al., "Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenic implications and clinical correlations", Blood, (20070000), vol. 109, no. 1, doi:10.1182/blood-2006-03-012948, pages 259 - 270, XP055547143

DOI:   http://dx.doi.org/10.1182/blood-2006-03-012948
    - AGATHANGELIDIS A. et al., "Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: A molecular classification with implications for targeted therapies", Blood, (20120000), vol. 119, pages 4467 - 4475
    - MINICI, C. et al., "Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukemia", Nature Comm., (20170000), vol. 8, page 15746
    - STAMATOPOULOS BSMITH TCROMPOT E et al., "The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study", Clin Cancer Res, (20180000), vol. 24, no. 20, pages 5048 - 5057
    - NADEU FROYO RCLOT G et al., "IGLV3-21 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics", Blood, (20210000), vol. 137, no. 21, doi:10.1182/blood.2020008311, pages 2935 - 2946, XP086581473

DOI:   http://dx.doi.org/10.1182/blood.2020008311
    - HOELLENRIEGEL JMEADOWS SASIVINA M et al., "The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia", Blood, (20110000), vol. 118, doi:10.1182/blood-2011-05-352492, pages 3603 - 3612, XP002676784

DOI:   http://dx.doi.org/10.1182/blood-2011-05-352492
    - HERMANN SEGORDON ALHERTLEIN E et al., "Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765", Blood, (20110000), vol. 117, doi:10.1182/blood-2011-01-328484, pages 6287 - 6296, XP008177912

DOI:   http://dx.doi.org/10.1182/blood-2011-01-328484
    - MAITY PCBILAL MKONING MT et al., "IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signalling", PNAS, (20200000), vol. 117, no. 8, pages 4320 - 4327
    - CHOTHIALESK, J Mol Biol, (19870000), vol. 196, pages 901 - 917
    - LEFRANC et al., "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig super-family V-like domains", Dev. Comp. Immunol., (20030000), vol. 27, pages 55 - 77
    - GAZZANO-SAN-TORO et al., J. Immunol. Methods, (19960000), vol. 202, page 163
    - KHORANA et al., J. Mol. Biol., (19710000), vol. 72, pages 209 - 217
    - DUHREN VON MINDEN et al., Nature, (20120000), vol. 489, pages 309 - 313
    - QI J et al., "An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies", Methods, (20190000), vol. 154, pages 70 - 76
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.